kuvura kanseri y'ibihaha itari mito

Kanseri y'ibihaha itari ntoya (NSCLC) ni ubwoko bwa kanseri y'ibihaha. Uburyo bwo kuvura NSCLC buratandukanye kandi bushingiye ku bintu byinshi, birimo icyiciro cya kanseri, ubuzima bw’umurwayi muri rusange, hamwe n’imihindagurikire y’imiterere y’imiterere y’ikibyimba. Aka gatabo karatanga incamake yuburyo nyamukuru bwo kuvura NSCLC, uhereye kubagwa no kuvura imirasire kugeza kuvura no gukingira indwara, guha ubushobozi abarwayi n’abarezi bafite ubumenyi bwo gufata ibyemezo byuzuye. Kumva Kanseri y’ibihaha itari ntoya.Kanseri y'ibihaha itari ntoya (NSCLC) ni itsinda rya kanseri y'ibihaha yitwara muburyo busa. Ubwoko nyamukuru bwa NSCLC burimo adenocarcinoma, kanseri y'udukoko twa kanseri, na kanseri nini. Kwipimisha neza, harimo gupima no gupima molekile, ni ngombwa muguhitamo ingamba nziza zo kuvura. Shandong Baofa Ikigo Cyubushakashatsi cya Kanseri cyahariwe ubushakashatsi bwa kanseri no guteza imbere uburyo bushya bwo kuvura, wige byinshi kuri https://baofahospital.com.Gutegura NSCLCNSCLC ikorwa hifashishijwe sisitemu ya TNM (Tumor, Node, Metastasis). Icyiciro gisobanura ubunini n'aho ikibyimba kibanza (T), niba kanseri yarakwirakwiriye hafi ya lymph node (N), ndetse na kanseri yanduye ahantu kure (M). Ibyiciro bitangirira kuri I (icyiciro cya mbere) kugeza kuri IV (icyiciro cyambere) .Ikizamini cya molekuline kuri NSCLCIbizamini bya molekuline byerekana ihinduka ryimiterere ya gene cyangwa proteine ​​zidasanzwe muri selile yibibyimba. Izi biomarkers zirashobora gufasha kumenya niba umurwayi ari umukandida wubuvuzi bugamije. Guhinduka bisanzwe birimo EGFR, ALK, ROS1, BRAF, nabandi. Ibisubizo byo gupima molekulari bigira ingaruka zikomeye kumyanzuro yo kuvura.Sandard Ubuvuzi bwa NSCLCKubaga Kubaga akenshi ni umurongo wambere wo kuvura icyiciro cya mbere cya NSCLC (icyiciro cya I na II). Intego ni ugukuraho ikibyimba hamwe na lymph node hafi. Ubwoko bwo kubaga burimo: Kurwanya Wedge: Gukuraho agace gato, kameze nk'igiti cy'ibihaha. Segmentectomy: Gukuraho igice kinini cyibihaha kuruta kwanga. Lobectomy: Gukuraho lobe yose yibihaha. Ubu ni uburyo busanzwe bwo kubaga NSCLC. Pneumonectomy: Gukuraho ibihaha byose. Ibi ntibisanzwe kandi bigenewe ibibyimba byinshi.Ubuvuzi bwa RadiyoyasiRadiation ivura ikoresha imirasire yingufu nyinshi kugirango yice selile. Irashobora gukoreshwa nkubuvuzi bwibanze, nyuma yo kubagwa kwica selile zose zisigaye, cyangwa kugabanya ibimenyetso (imirasire ya palliative). Ubwoko butandukanye bwo kuvura imirasire harimo: Ubuvuzi bwo hanze bwimirasire (EBRT): Imirasire itangwa mumashini hanze yumubiri. Ubuvuzi bwa stereotactique yumubiri (SBRT): Gutanga urugero rwinshi rwimirasire kumwanya muto, neza neza. Akenshi ikoreshwa mubyiciro byambere NSCLC mugihe kubaga atari amahitamo. Brachytherapy (Imishwarara Yimbere): Ibikoresho bya radiyo bishyirwa imbere yibibyimba cyangwa hafi yacyo.ChemotherapyChemotherapy ikoresha imiti yica kanseri ya kanseri mumubiri. Bikunze gukoreshwa muburyo bwo kubaga cyangwa kuvura imirasire, cyangwa nkubuvuzi bwibanze bwo gutera imbere NSCLC. Imiti isanzwe ya chimiotherapie kuri NSCLC irimo cisplatine, karboplatine, paclitaxel, docetaxel, pemetrexed, na gemcitabine. Ubuvuzi bugenewe Ubuvuzi bwa NSCLCUbuvuzi bugamije ni imiti yibasira molekile zihariye zigira uruhare mu mikurire ya kanseri no kubaho. Ubu buryo bwo kuvura bugira akamaro gusa mugihe ikibyimba gifite ihinduka ryimiterere yihariye ya poroteyine cyangwa proteine idasanzwe. NSCLC hamwe na EGFR ihinduka. Iyi miti ihagarika poroteyine ya EGFR, ifasha selile kanseri gukura. Ingero zirimo: Gefitinib (Iressa) Erlotinib (Tarceva) Afatinib (Gilotrif) Osimertinib (Tagrisso) ALK InhibitorALK (anaplastique lymphoma kinase) ikoreshwa mu kuvura NSCLC hamwe na ALK ya gen. Iyi miti ihagarika poroteyine ALK, ifasha kanseri ikura. Ingero zirimo: Crizotinib (Xalkori) Ceritinib (Zykadia) Alectinib (Alecensa) Brigatinib (Alunbrig) Lorlatinib (Lorbrena) ROS1 InhibitorROS1 ikoreshwa mu kuvura NSCLC hamwe na ROS1 gen. Iyi miti ihagarika poroteyine ya ROS1, ifasha kanseri ikura. Ingero zirimo: Crizotinib (Xalkori) Entrectinib (Rozlytrek) BRAF InhibitorBRAF inhibitor zikoreshwa mukuvura NSCLC hamwe na BRAF V600E ihinduka. Iyi miti ihagarika poroteyine ya BRAF. Ingero zirimo: Dabrafenib (Tafinlar) Trametinib (Mekinist) (ikoreshwa ifatanije na Dabrafenib) Ubundi buvuzi bugamije Ubundi buvuzi bugamije bushobora gukoreshwa bitewe na mutation yihariye igaragara mu kibyimba. Ingero zirimo RET inhibitor (kuri RET fusion) na MET inhibitor (kuri MET exon 14 gusimbuka mutation) .Immunotherapy ya Ubuvuzi bwa NSCLCImiti ikingira indwara ifasha umubiri wumubiri kurwanya kanseri. Bakora bahagarika poroteyine zibuza sisitemu yumubiri kwibasira selile. Ibi bikunze gukoreshwa muri NSCLC kwivuza. Ingero zirimo: Pembrolizumab (Keytruda) Nivolumab (Opdivo) Atezolizumab (Tecentriq) Durvalumab (Imfinzi) Cemiplimab (Libtayo) CTLA-4 InhibitorCTLA-4 (cytotoxic T-lymphocyte ifitanye isano na proteine ​​4) ibuza poroteyine ya CTLA-4. Urugero ni Ipilimumab (Yervoy), ikoreshwa kenshi hamwe na PD-1 inhibitor.Guhuza UbuvuziOften, Ubuvuzi bwa NSCLC shyiramo uburyo bwo kuvura butandukanye. Kurugero, kubaga bishobora gukurikirwa na chimiotherapie cyangwa imiti ivura imirasire. Ubuvuzi bugenewe cyangwa immunotherapy bushobora guhuzwa na chimiotherapie. Ihuriro ryihariye rizaterwa nuburwayi bwa buri muntu. Kugirango umenye byinshi kubyerekeye gusura kanseri Shandong Baofa Ikigo Cyubushakashatsi Kanseri.Igeragezwa rya Clinical Ibigeragezo byubushakashatsi nubushakashatsi busuzuma uburyo bushya bwo kuvura cyangwa guhuza imiti. Abarwayi hamwe NSCLC irashobora gutekereza kwitabira ibizamini byubuvuzi kugirango igere ku buvuzi bugezweho. Amakuru yerekeye ibizamini byamavuriro murashobora kubisanga kurubuga rwikigo cyigihugu cya kanseri hamwe nandi masoko azwi Ubuvuzi bwa NSCLC birashobora gutera ingaruka. Ni ngombwa kuganira n'ingaruka zishobora guterwa na muganga wawe kandi ukamenya kubikemura. Kwita ku nkunga, nko gucunga ububabare no gushyigikira imirire, birashobora gufasha kuzamura imibereho mugihe cyo kuvura.Prognoz hamwe na Care-Gukurikirana Ubuvuzi bwa prognoza ya NSCLC biterwa nicyiciro cya kanseri, ubuzima bwumurwayi muri rusange, nuburyo kanseri yitabira kwivuza. Guhora mukurikirana gahunda ni ngombwa mugukurikirana ibisubirwamo no gucunga ingaruka zose z'igihe kirekire zo kuvura.Inshingano: Iyi ngingo itanga amakuru rusange yerekeye kuvura kanseri y'ibihaha itari nto (NSCLC) kandi ntigomba gufatwa nkinama zubuvuzi. Buri gihe ujye ubaza umuganga wawe cyangwa undi muntu winzobere mu buvuzi wujuje ibisabwa kugira ngo aguhe ibyifuzo byihariye bijyanye n'ubuvuzi bwawe bwihariye.